IP Library › Granted Patent US 12,203,094

Granted Patent B2

US 12,203,094 · App. 17/073,862 · Granted Jan 21, 2025

Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof

Inventors: Albert Barnes Seymour (Westborough, MA); Seemin Seher Ahmed (Worcester, MA); Jason Boke Wright (Concord, MA); Serena Nicole Dollive (Waltham, MA); James Anthony McSwiggen (Arlington, MA); Jaime Michelle Prout (Hudson, NH); Danielle Lauren Sookiasian (Quincy, MA)

Assignee: Homology Medicines, Inc.

C12N15/907 A61K35/761 C12N7/00 C12N2710/10033 C12N2710/10052 C12N2750/14121 C12N2750/14143

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,203,094
App. No.: 17/073,862
Granted: Jan 21, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Provided herein are adeno-associated virus (AAV) compositions that can restore phenylalanine hydroxylase (PAH) gene function in cell. Also provided are methods of use of the AAV compositions, and packaging systems for making the AAV compositions.

Claims (76)

1. A replication-defective adeno-associated virus (AAV) comprising:

(a) an AAV capsid; and

(b) a correction genome comprising:

(i) an editing element for editing a target locus in a human phenylalanine hydroxylase (PAH) gene, wherein the editing element comprises a nucleotide sequence that is at least 90% identical to the nucleotide sequence set forth in SEQ ID NO: 35, 83, or 84;

(ii) a 5′ homology arm located 5′ of the editing element, the 5′ homology arm comprising a nucleotide sequence of at least 100 nucleotides in length, that is at least 90% identical to a nucleic acid sequence contained within the nucleic acid sequence set forth in SEQ ID NO: 36, 37, 38, 39, 40, 41, 42, 43, 44, or 115; and

(iii) a 3′ homology arm located 3′ of the editing element, the 3′ homology arm comprising a nucleotide sequence of at least 100 nucleotides in length, that is at least 90% identical to a nucleic acid sequence contained within the nucleic acid sequence set forth in SEQ ID NO: 45 or 117.

2. The AAV of claim 1 , wherein each of the 5′ and 3′ homology arm nucleotide sequences independently has a length of about 100 to about 2000 nucleotides.

3. The AAV of claim 1 , wherein: the 5′ homology arm is at least 90% identical to the nucleotide sequence set forth in SEQ ID NO: 36, 37, 38, 39, 40, 41, 42, 43, 44, or 115; and/or the 3′ homology arm is at least 90% identical to the nucleotide sequence set forth in SEQ ID NO: 45 or 117.

4. The AAV of claim 1 , wherein:

the 5′ homology arm comprises:

C corresponding to nucleotide-2 of the PAH gene, G corresponding to nucleotide 4 of the PAH gene, G corresponding to nucleotide 6 of the PAH gene, G corresponding to nucleotide 7 of the PAH gene, G corresponding to nucleotide 9 of the PAH gene, A corresponding to nucleotide-467 of the PAH gene, A corresponding to nucleotide-465 of the PAH gene, A corresponding to nucleotide-181 of the PAH gene, G corresponding to nucleotide-214 of the PAH gene, C corresponding to nucleotide-212 of the PAH gene, A corresponding to nucleotide-211 of the PAH gene, G corresponding to nucleotide 194 of the PAH gene, C corresponding to nucleotide-433 of the PAH gene, C corresponding to nucleotide-432 of the PAH gene, ACGCTGTTCTTCGCC (SEQ ID NO: 68) corresponding to nucleotides-394 to-388 of the PAH gene, A corresponding to nucleotide-341 of the PAH gene, A corresponding to nucleotide-339 of the PAH gene, A corresponding to nucleotide-225 of the PAH gene, A corresponding to nucleotide-211 of the PAH gene, and/or A corresponding to nucleotide-203 of the PAH gene;

the 5′ homology arm comprises:

(a) C corresponding to nucleotide-2 of the PAH gene, G corresponding to nucleotide 4 of the PAH gene, G corresponding to nucleotide 6 of the PAH gene, G corresponding to nucleotide 7 of the PAH gene, and G corresponding to nucleotide 9 of the PAH gene;

(b) A corresponding to nucleotide-467 of the PAH gene, and A corresponding to nucleotide-465 of the PAH gene;

(d) G corresponding to nucleotide-214 of the PAH gene, C corresponding to nucleotide -212 of the PAH gene, and A corresponding to nucleotide-211 of the PAH gene;

(e) G corresponding to nucleotide 194 of the PAH gene;

(f) C corresponding to nucleotide-433 of the PAH gene, and C corresponding to nucleotide-432 of the PAH gene;

(g) ACGCTGTTCTTCGCC (SEQ ID NO: 68) corresponding to nucleotides-394 to -388 of the PAH gene; and/or

(h) A corresponding to nucleotide-341 of the PAH gene, A corresponding to nucleotide -339 of the PAH gene, A corresponding to nucleotide-225 of the PAH gene, A corresponding to nucleotide-211 of the PAH gene, and A corresponding to nucleotide -203 of the PAH gene; or

the 5′ homology arm comprises the modifications of (c) and (d), (f) and (g), and/or (b) and (h).

5. The AAV of claim 1 , wherein: the 5′ homology arm comprises the nucleotide sequence set forth in SEQ ID NO: 36, 37, 38, 39, 40, 41, 42, 43, 44, or 115; and/or the 3′ homology arm comprises the nucleotide sequence set forth in SEQ ID NO: 45 or 117.

6. The AAV claim 1 , wherein: the nucleic acid sequence of the 5′ homology arm consists of the sequence set forth in SEQ ID NO: 36, 37, 38, 39, 40, 41, 42, 43, 44, or 115; and/or the nucleic acid sequence of the 3′ homology arm consists of the sequence set forth in SEQ ID NO: 45 or 117.

7. The AAV of claim 1 , wherein the editing element comprises a PAH coding sequence, optionally wherein:

the PAH coding sequence encodes an amino acid sequence set forth in SEQ ID NO: 23;

the PAH coding sequence is silently altered, optionally wherein the PAH coding sequence comprises the sequence set forth in SEQ ID NO: 25, 116, 131, 132, 138, 139, or 143.

8. The AAV of claim 1 , wherein the editing element comprises a PAH intron-inserted coding sequence, optionally wherein the PAH intron-inserted coding sequence comprises a nonnative intron inserted in a PAH coding sequence, optionally wherein:

the nonnative intron is selected from the group consisting of a first intron of a hemoglobin beta gene and a minute virus in mice (MVM) intron;

the nucleotide sequence of the nonnative intron consists of a nucleotide sequence at least 90% identical to the nucleotide sequence set forth in any one of SEQ ID NOs: 28-30, and 120-130;

the nucleotide sequence of the nonnative intron consists of the nucleotide sequence set forth in any one of SEQ ID NOs: 28-30, and 120-130; and/or

the PAH intron-inserted coding sequence encodes an amino acid sequence set forth in SEQ ID NO: 23.

9. The AAV of claim 8 , wherein the PAH intron-inserted coding sequence comprises, from 5′ to 3′: a first portion of a PAH coding sequence, the intron, and a second portion of a PAH coding sequence, wherein the first portion and the second portion, when spliced together, form a complete PAH coding sequence, optionally wherein:

the PAH coding sequence is silently altered;

the PAH coding sequence comprises the nucleotide sequence set forth in SEQ ID NO: 25, 116, 131, 132, 138, 139, or 143;

the first portion of the PAH coding sequence comprises the nucleotide sequence set forth in

SEQ ID NO: 64 or 65, and/or the second portion of the PAH coding sequence comprises the nucleotide sequence set forth in SEQ ID NO: 66 or 67; and/or

the first portion of the PAH coding sequence consists of the nucleotide sequence set forth in SEQ ID NO: 64 or 65, and the second portion of the PAH coding sequence consists of the nucleotide sequence set forth in SEQ ID NO: 66 or 67.

10. The AAV of claim 1 , wherein the editing element comprises, from 5′ to 3′: a ribosomal skipping element, and a PAH coding sequence or a PAH intron-inserted coding sequence, optionally wherein the editing element further comprises a polyadenylation sequence 3′ to the PAH coding sequence or the PAH intron-inserted coding sequence, optionally wherein the polyadenylation sequence is an exogenous polyadenylation sequence, optionally wherein the exogenous polyadenylation sequence is an SV40 polyadenylation sequence, optionally wherein the SV40 polyadenylation sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 31-34.

11. The AAV of claim 1 , wherein the nucleotide 5′ to the target locus is in an intron of the PAH gene, optionally in intron 1 of the PAH gene.

12. The AAV of claim 1 , wherein the editing element comprises a nucleotide sequence that is at least 99% identical to the nucleotide sequence set forth in SEQ ID NO: 35, 83, or 84.

13. The AAV of claim 1 , wherein the correction genome comprises a nucleotide sequence that is at least 90% identical to the nucleotide sequence set forth in any one of SEQ ID NOs: 46-54, 118, 136, and 145.

14. The AAV of claim 1 , wherein the correction genome further comprises a 5′ inverted terminal repeat (5′ ITR) nucleotide sequence 5′ of the 5′ homology arm nucleotide sequence, and a 3′ inverted terminal repeat (3′ ITR) nucleotide sequence 3′ of the 3′ homology arm nucleotide sequence, optionally wherein:

(a) the 5′ ITR nucleotide sequence has at least 95% sequence identity to SEQ ID NO: 18, and the 3′ ITR nucleotide sequence has at least 95% sequence identity to SEQ ID NO: 19;

(b) the 5′ ITR nucleotide sequence has at least 95% sequence identity to SEQ ID NO: 20, and the 3′ ITR nucleotide sequence has at least 95% sequence identity to SEQ ID NO: 21; or

(c) the 5′ ITR nucleotide sequence has at least 95% sequence identity to SEQ ID NO: 26, and the 3′ ITR nucleotide sequence has at least 95% sequence identity to SEQ ID NO: 27.

15. The AAV of claim 1 , wherein the correction genome comprises a nucleotide sequence that is at least 90% identical to the nucleotide sequence set forth in any one of SEQ ID NOs: 55-63, 119, 135, 137, and 146.

16. The AAV of claim 1 , wherein the AAV capsid comprises: an AAV capsid protein comprising an amino acid sequence having at least 95% sequence identity with the amino acid sequence of amino acids 203-736 of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, or 17, optionally wherein:

the amino acid in the capsid protein corresponding to amino acid 206 of SEQ ID NO: 2 is C; the amino acid in the capsid protein corresponding to amino acid 296 of SEQ ID NO: 2 is H; the amino acid in the capsid protein corresponding to amino acid 312 of SEQ ID NO: 2 is Q; the amino acid in the capsid protein corresponding to amino acid 346 of SEQ ID NO: 2 is A; the amino acid in the capsid protein corresponding to amino acid 464 of SEQ ID NO: 2 is N; the amino acid in the capsid protein corresponding to amino acid 468 of SEQ ID NO: 2 is S; the amino acid in the capsid protein corresponding to amino acid 501 of SEQ ID NO: 2 is I; the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R; the amino acid in the capsid protein corresponding to amino acid 590 of SEQ ID NO: 2 is R; the amino acid in the capsid protein corresponding to amino acid 626 of SEQ ID NO: 2 is G or Y; the amino acid in the capsid protein corresponding to amino acid 681 of SEQ ID NO: 2 is M; the amino acid in the capsid protein corresponding to amino acid 687 of SEQ ID NO: 2 is R; the amino acid in the capsid protein corresponding to amino acid 690 of SEQ ID NO: 2 is K; the amino acid in the capsid protein corresponding to amino acid 706 of SEQ ID NO: 2 is C; or, the amino acid in the capsid protein corresponding to amino acid 718 of SEQ ID NO: 2 is G;

(a) the amino acid in the capsid protein corresponding to amino acid 626 of SEQ ID NO: 2 is G, and the amino acid in the capsid protein corresponding to amino acid 718 of SEQ ID NO: 2 is G;

(b) the amino acid in the capsid protein corresponding to amino acid 296 of SEQ ID NO: 2 is H, the amino acid in the capsid protein corresponding to amino acid 464 of SEQ ID NO: 2 is N, the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R, and the amino acid in the capsid protein corresponding to amino acid 681 of SEQ ID NO: 2 is M;

(c) the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R, and the amino acid in the capsid protein corresponding to amino acid 687 of SEQ ID NO: 2 is R;

(d) the amino acid in the capsid protein corresponding to amino acid 346 of SEQ ID NO: 2 is A, and the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R;

(e) the amino acid in the capsid protein corresponding to amino acid 501 of SEQ ID NO: 2 is I, the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R, and the amino acid in the capsid protein corresponding to amino acid 706 of SEQ ID NO: 2 is C; and/or

the AAV capsid protein comprises the amino acid sequence of amino acids 203-736 of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, or 17.

17. The AAV of claim 1 , wherein the AAV capsid comprises: an AAV capsid protein comprising an amino acid sequence having at least 95% sequence identity with the amino acid sequence of amino acids 138-736 of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, or 17, optionally wherein:

the amino acid in the capsid protein corresponding to amino acid 151 of SEQ ID NO: 2 is R; the amino acid in the capsid protein corresponding to amino acid 160 of SEQ ID NO: 2 is D; the amino acid in the capsid protein corresponding to amino acid 206 of SEQ ID NO: 2 is C; the amino acid in the capsid protein corresponding to amino acid 296 of SEQ ID NO: 2 is H; the amino acid in the capsid protein corresponding to amino acid 312 of SEQ ID NO: 2 is Q; the amino acid in the capsid protein corresponding to amino acid 346 of SEQ ID NO: 2 is A; the amino acid in the capsid protein corresponding to amino acid 464 of SEQ ID NO: 2 is N; the amino acid in the capsid protein corresponding to amino acid 468 of SEQ ID NO: 2 is S; the amino acid in the capsid protein corresponding to amino acid 501 of SEQ ID NO: 2 is I; the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R; the amino acid in the capsid protein corresponding to amino acid 590 of SEQ ID NO: 2 is R; the amino acid in the capsid protein corresponding to amino acid 626 of SEQ ID NO: 2 is G or Y; the amino acid in the capsid protein corresponding to amino acid 681 of SEQ ID NO: 2 is M; the amino acid in the capsid protein corresponding to amino acid 687 of SEQ ID NO: 2 is R; the amino acid in the capsid protein corresponding to amino acid 690 of SEQ ID NO: 2 is K; the amino acid in the capsid protein corresponding to amino acid 706 of SEQ ID NO: 2 is C; or, the amino acid in the capsid protein corresponding to amino acid 718 of SEQ ID NO: 2 is G;

(a) the amino acid in the capsid protein corresponding to amino acid 626 of SEQ ID NO: 2 is G, and the amino acid in the capsid protein corresponding to amino acid 718 of SEQ ID NO: 2 is G;

(c) the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R, and the amino acid in the capsid protein corresponding to amino acid 687 of SEQ ID NO: 2 is R;

(d) the amino acid in the capsid protein corresponding to amino acid 346 of SEQ ID NO: 2 is A, and the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R; or

the AAV capsid protein comprises the amino acid sequence of amino acids 138-736 of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, or 17.

18. The AAV of claim 1 , wherein the AAV capsid comprises: an AAV capsid protein comprising an amino acid sequence having at least 95% sequence identity with the amino acid sequence of amino acids 1-736 of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, or 17, optionally wherein:

the amino acid in the capsid protein corresponding to amino acid 2 of SEQ ID NO: 2 is T; the amino acid in the capsid protein corresponding to amino acid 65 of SEQ ID NO: 2 is I; the amino acid in the capsid protein corresponding to amino acid 68 of SEQ ID NO: 2 is V; the amino acid in the capsid protein corresponding to amino acid 77 of SEQ ID NO: 2 is R; the amino acid in the capsid protein corresponding to amino acid 119 of SEQ ID NO: 2 is L; the amino acid in the capsid protein corresponding to amino acid 151 of SEQ ID NO: 2 is R; the amino acid in the capsid protein corresponding to amino acid 160 of SEQ ID NO: 2 is D; the amino acid in the capsid protein corresponding to amino acid 206 of SEQ ID NO: 2 is C; the amino acid in the capsid protein corresponding to amino acid 296 of SEQ ID NO: 2 is H; the amino acid in the capsid protein corresponding to amino acid 312 of SEQ ID NO: 2 is Q; the amino acid in the capsid protein corresponding to amino acid 346 of SEQ ID NO: 2 is A; the amino acid in the capsid protein corresponding to amino acid 464 of SEQ ID NO: 2 is N; the amino acid in the capsid protein corresponding to amino acid 468 of SEQ ID NO: 2 is S; the amino acid in the capsid protein corresponding to amino acid 501 of SEQ ID NO: 2 is I; the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R; the amino acid in the capsid protein corresponding to amino acid 590 of SEQ ID NO: 2 is R; the amino acid in the capsid protein corresponding to amino acid 626 of SEQ ID NO: 2 is G or Y; the amino acid in the capsid protein corresponding to amino acid 681 of SEQ ID NO: 2 is M; the amino acid in the capsid protein corresponding to amino acid 687 of SEQ ID NO: 2 is R; the amino acid in the capsid protein corresponding to amino acid 690 of SEQ ID NO: 2 is K; the amino acid in the capsid protein corresponding to amino acid 706 of SEQ ID NO: 2 is C; or, the amino acid in the capsid protein corresponding to amino acid 718 of SEQ ID NO: 2 is G;

(a) the amino acid in the capsid protein corresponding to amino acid 2 of SEQ ID NO: 2 is T, and the amino acid in the capsid protein corresponding to amino acid 312 of SEQ ID NO: 2 is Q;

(b) the amino acid in the capsid protein corresponding to amino acid 65 of SEQ ID NO: 2 is I, and the amino acid in the capsid protein corresponding to amino acid 626 of SEQ ID NO: 2 is Y;

(c) the amino acid in the capsid protein corresponding to amino acid 77 of SEQ ID NO: 2 is R, and the amino acid in the capsid protein corresponding to amino acid 690 of SEQ ID NO: 2 is K;

(d) the amino acid in the capsid protein corresponding to amino acid 119 of SEQ ID NO: 2 is L, and the amino acid in the capsid protein corresponding to amino acid 468 of SEQ ID NO: 2 is S;

(e) the amino acid in the capsid protein corresponding to amino acid 626 of SEQ ID NO: 2 is G, and the amino acid in the capsid protein corresponding to amino acid 718 of SEQ ID NO: 2 is G;

(f) the amino acid in the capsid protein corresponding to amino acid 296 of SEQ ID NO: 2 is H, the amino acid in the capsid protein corresponding to amino acid 464 of SEQ ID NO: 2 is N, the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R, and the amino acid in the capsid protein corresponding to amino acid 681 of SEQ ID NO: 2 is M;

(g) the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R, and the amino acid in the capsid protein corresponding to amino acid 687 of SEQ ID NO: 2 is R;

(h) the amino acid in the capsid protein corresponding to amino acid 346 of SEQ ID NO: 2 is A, and the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R; or

(i) the amino acid in the capsid protein corresponding to amino acid 501 of SEQ ID NO: 2 is I, the amino acid in the capsid protein corresponding to amino acid 505 of SEQ ID NO: 2 is R, and the amino acid in the capsid protein corresponding to amino acid 706 of SEQ ID NO: 2 is C; and/or

the AAV capsid protein comprises the amino acid sequence of amino acids 1-736 of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, or 17.

19. A pharmaceutical composition comprising the AAV of claim 1 .

20. A polynucleotide comprising the nucleic acid sequence of any one of SEQ ID NO: 25, 46-63, 80-82, 116, 118, 119, 131, 132, 135-139, 143, 145, or 146, optionally wherein the polynucleotide is comprised within a vector or host cell.

Assignments (3)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2025

From: Q32 BIO, INC.

To: CITY OF HOPE

Reel/Frame 070700/0903 →

CHANGE OF NAME Recorded Mar 18, 2025

From: HOMOLOGY MEDICINES, INC.

To: Q32 BIO INC.

Reel/Frame 070542/0562 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2022

From: SEYMOUR, ALBERT BARNES; AHMED, SEEMIN SEHER; WRIGHT, JASON BOKE; DOLLIVE, SERENA NICOLE; MCSWIGGEN, JAMES ANTHONY; PROUT, JAIME MICHELLE; SOOKIASIAN, DANIELLE LAUREN

To: HOMOLOGY MEDICINES, INC.

Reel/Frame 061225/0625 →

Continuity (4)

Continuation PCTUS2019016354 · Feb 1, 2019

Provisional Application 62672377 · May 16, 2018

Provisional Application 62625149 · Feb 1, 2018

Related Publication 20210130794A1 · May 6, 2021

References Cited (195)

US 5252479A · Srivastava · 1993 [cited by applicant]

US 5474935A · Chatterjee et al. · 1995 [cited by applicant]

US 5589377A · Lebkowski et al. · 1996 [cited by applicant]

US 5622856A · Natsoulis · 1997 [cited by applicant]

US 5650309A · Wong-Staal et al. · 1997 [cited by applicant]

US 5753500A · Shenk et al. · 1998 [cited by applicant]

US 5780447A · Nienhuis · 1998 [cited by applicant]

US 5895759A · Strauss et al. · 1999 [cited by applicant]

US 6025195A · Sandig et al. · 2000 [cited by applicant]

US 6153436A · Hermonat et al. · 2000 [cited by applicant]

US 6156303A · Russell et al. · 2000 [cited by applicant]

US 6180613B1 · Kaplitt et al. · 2001 [cited by applicant]

US 6238914B1 · Boyce · 2001 [cited by applicant]

US 6268212B1 · Simonet · 2001 [cited by applicant]

US 6329181B1 · Xiao et al. · 2001 [cited by applicant]

US 6338962B1 · Boyce · 2002 [cited by applicant]

US 6387670B1 · Leblois-Prehaud et al. · 2002 [cited by applicant]

US 6610906B1 · Kurachi et al. · 2003 [cited by applicant]

US 6759237B1 · Wilson et al. · 2004 [cited by applicant]

US 6919209B1 · Chatterjee et al. · 2005 [cited by applicant]

US 6924128B2 · Allen · 2005 [cited by applicant]

US 6936243B2 · Snyder et al. · 2005 [cited by applicant]

US 6936466B2 · Feldhaus · 2005 [cited by applicant]

US 6953690B1 · Gao et al. · 2005 [cited by applicant]

US 6984517B1 · Chiorini et al. · 2006 [cited by applicant]

US 7001764B2 · Little et al. · 2006 [cited by applicant]

US 7022519B2 · Gao et al. · 2006 [cited by applicant]

US 7056502B2 · Hildinger et al. · 2006 [cited by applicant]

US 7091029B2 · Hwang · 2006 [cited by applicant]

US 7094604B2 · Snyder et al. · 2006 [cited by applicant]

US 7148341B2 · Kleinschmidt et al. · 2006 [cited by applicant]

US 7157571B2 · Wang et al. · 2007 [cited by applicant]

US 7172893B2 · Rabinowitz et al. · 2007 [cited by applicant]

US 7179903B2 · McArthur et al. · 2007 [cited by applicant]

US 7198951B2 · Gao et al. · 2007 [cited by applicant]

US 7220577B2 · Zolotukhin · 2007 [cited by applicant]

US 7235393B2 · Gao et al. · 2007 [cited by applicant]

US 7259151B2 · Arbetman et al. · 2007 [cited by applicant]

US 7282199B2 · Gao et al. · 2007 [cited by applicant]

US 7351813B2 · Miao et al. · 2008 [cited by applicant]

US 7465583B2 · Samulski et al. · 2008 [cited by applicant]

US 7482156B2 · Arroyo et al. · 2009 [cited by applicant]

US 7588772B2 · Kay et al. · 2009 [cited by applicant]

US 7749492B2 · Bartlett et al. · 2010 [cited by applicant]

US 7790154B2 · Samulski et al. · 2010 [cited by applicant]

US 7906111B2 · Wilson et al. · 2011 [cited by applicant]

US 8030065B2 · Gray · 2011 [cited by applicant]

US 8067156B2 · Kaplitt et al. · 2011 [cited by applicant]

US 8163543B2 · Urabe et al. · 2012 [cited by applicant]

US 8168425B2 · Gray · 2012 [cited by applicant]

US 8241622B2 · Englehardt et al. · 2012 [cited by applicant]

US 8283151B2 · Schmidt et al. · 2012 [cited by applicant]

US 8298818B2 · Boye et al. · 2012 [cited by applicant]

US 8476418B2 · Mueller et al. · 2013 [cited by applicant]

US 8524446B2 · Gao et al. · 2013 [cited by applicant]

US 8628966B2 · Chatterjee et al. · 2014 [cited by applicant]

US 8632764B2 · Xiao et al. · 2014 [cited by applicant]

US 8716461B2 · Delwart et al. · 2014 [cited by applicant]

US 8846387B2 · Russell et al. · 2014 [cited by applicant]

US 8846389B2 · Chiorini et al. · 2014 [cited by applicant]

US 8926958B2 · Shah et al. · 2015 [cited by applicant]

US 8999678B2 · Vandenberghe et al. · 2015 [cited by applicant]

US 8999948B2 · Tubert et al. · 2015 [cited by applicant]

US 9114161B2 · Barkats · 2015 [cited by applicant]

US 9150882B2 · Kay et al. · 2015 [cited by applicant]

US 9169299B2 · Lisowski et al. · 2015 [cited by applicant]

US 9169494B2 · Hewitt et al. · 2015 [cited by applicant]

US 9193956B2 · Schaffer et al. · 2015 [cited by applicant]

US 9217155B2 · Gao et al. · 2015 [cited by applicant]

US 9222105B2 · Cost et al. · 2015 [cited by applicant]

US 9402919B2 · Roeth et al. · 2016 [cited by applicant]

US 9408904B2 · Wright et al. · 2016 [cited by applicant]

US 9409953B2 · Asokan et al. · 2016 [cited by applicant]

US 9441244B2 · Schaffer et al. · 2016 [cited by applicant]

US 9617548B2 · Chuah et al. · 2017 [cited by applicant]

US 9623120B2 · Chatterjee et al. · 2017 [cited by applicant]

US 9764045B2 · Nathwani et al. · 2017 [cited by applicant]

US 9783824B2 · Kay et al. · 2017 [cited by applicant]

US 9840719B2 · High et al. · 2017 [cited by applicant]

US 9890396B2 · Chatterjee et al. · 2018 [cited by applicant]

US 9926574B2 · Barkats · 2018 [cited by applicant]

US 20030129203A1 · Vega et al. · 2003 [cited by applicant]

US 20030130221A1 · High et al. · 2003 [cited by applicant]

US 20030198620A1 · Ozawa et al. · 2003 [cited by applicant]

US 20040086485A1 · Aguilar-Cordova · 2004 [cited by applicant]

US 20040142416A1 · Laipis et al. · 2004 [cited by applicant]

US 20040235174A1 · Grimm et al. · 2004 [cited by applicant]

US 20050112765A1 · Li et al. · 2005 [cited by applicant]

US 20090191597A1 · Samulski et al. · 2009 [cited by applicant]

US 20090215879A1 · Diprimio et al. · 2009 [cited by applicant]

US 20100297084A1 · Bennett et al. · 2010 [cited by applicant]

US 20110294218A1 · Chatterjee · 2011 [cited by examiner]

US 20120046349A1 · Bell et al. · 2012 [cited by applicant]

US 20120093772A1 · Horsager et al. · 2012 [cited by applicant]

US 20120244127A1 · Lipschutz et al. · 2012 [cited by applicant]

US 20130023033A1 · Wilson et al. · 2013 [cited by applicant]

US 20130189225A1 · Voit et al. · 2013 [cited by applicant]

US 20130280222A1 · Kay et al. · 2013 [cited by applicant]

US 20130287736A1 · Passini et al. · 2013 [cited by applicant]

US 20130310443A1 · Srivastava et al. · 2013 [cited by applicant]

US 20130323226A1 · Wilson et al. · 2013 [cited by applicant]

US 20140037585A1 · Wright et al. · 2014 [cited by applicant]

US 20140050701A1 · Zhong et al. · 2014 [cited by applicant]

US 20140107185A1 · Maclaren et al. · 2014 [cited by applicant]

US 20140271550A1 · Rabinowitz et al. · 2014 [cited by applicant]

US 20140336245A1 · Mingozzi et al. · 2014 [cited by applicant]

US 20140359799A1 · Wang et al. · 2014 [cited by applicant]

US 20150023924A1 · High et al. · 2015 [cited by applicant]

US 20150024467A1 · Sheldon et al. · 2015 [cited by applicant]

US 20150065562A1 · Yazicioglu et al. · 2015 [cited by applicant]

US 20150079038A1 · Deverman et al. · 2015 [cited by applicant]

US 20150110762A1 · Holmes et al. · 2015 [cited by applicant]

US 20150111955A1 · High et al. · 2015 [cited by applicant]

US 20150184197A1 · Davidson et al. · 2015 [cited by applicant]

US 20150232836A1 · Krieg · 2015 [cited by examiner]

US 20150238550A1 · McCown et al. · 2015 [cited by applicant]

US 20150252384A1 · Kaspar et al. · 2015 [cited by applicant]

US 20150315610A1 · Nishie et al. · 2015 [cited by applicant]

US 20150352228A1 · Torbett et al. · 2015 [cited by applicant]

US 20150374803A1 · Wolfe · 2015 [cited by applicant]

US 20150376240A1 · Cronin et al. · 2015 [cited by applicant]

US 20150376650A1 · Auerbach et al. · 2015 [cited by applicant]

US 20160000887A1 · Wilson et al. · 2016 [cited by applicant]

US 20160017295A1 · Schaffer et al. · 2016 [cited by applicant]

US 20160032319A1 · Wright et al. · 2016 [cited by applicant]

US 20160123990A1 · High et al. · 2016 [cited by applicant]

US 20160175365A1 · Golden · 2016 [cited by applicant]

US 20160229904A1 · Xiao et al. · 2016 [cited by applicant]

US 20170088856A1 · Barzel et al. · 2017 [cited by applicant]

US 20170119906A1 · Riley · 2017 [cited by applicant]

US 20170145439A1 · Gao et al. · 2017 [cited by applicant]

US 20170326256A1 · Doering et al. · 2017 [cited by applicant]

US 20180298380A1 · Gao et al. · 2018 [cited by applicant]

EP 126544A2 · 1984 [cited by applicant]

EP 161788A1 · 1985 [cited by applicant]

EP 746624A1 · 1996 [cited by applicant]

EP 1497436A1 · 2005 [cited by applicant]

WO WO1996008560A1 · 1996 [cited by applicant]

WO WO1998009524A1 · 1998 [cited by applicant]

WO WO1998021349A1 · 1998 [cited by applicant]

WO WO1998027207A1 · 1998 [cited by applicant]

WO WO1998028417A1 · 1998 [cited by applicant]

WO WO1999003981A1 · 1999 [cited by applicant]

WO WO1999018227A1 · 1999 [cited by applicant]

WO WO1999055564A1 · 1999 [cited by applicant]

WO WO1999064569A1 · 1999 [cited by applicant]

WO WO2000049160A1 · 2000 [cited by applicant]

WO WO2001036620A2 · 2001 [cited by applicant]

WO WO2002066611A2 · 2002 [cited by applicant]

WO WO2003052051A2 · 2003 [cited by applicant]

WO WO2003087383A1 · 2003 [cited by applicant]

WO WO2003093436A2 · 2003 [cited by applicant]

WO WO2005111220A2 · 2005 [cited by applicant]

WO WO2006096815A2 · 2006 [cited by applicant]

WO WO2007019646A1 · 2007 [cited by applicant]

WO WO2008021140A2 · 2008 [cited by applicant]

WO WO2009000552A2 · 2008 [cited by applicant]

WO WO2009130208A1 · 2009 [cited by applicant]

WO WO2009134681A2 · 2009 [cited by applicant]

WO WO2010124180A1 · 2010 [cited by applicant]

WO WO2011038187A1 · 2011 [cited by applicant]

WO WO2014064277A1 · 2014 [cited by applicant]

WO WO2014089212A1 · 2014 [cited by applicant]

WO WO2014193716A2 · 2014 [cited by applicant]

WO WO2015061491A1 · 2015 [cited by applicant]

WO WO2015143177A1 · 2015 [cited by applicant]

WO WO2015164723A1 · 2015 [cited by applicant]

WO WO2016049230A1 · 2016 [cited by applicant]

WO WO2016097218A1 · 2016 [cited by applicant]

WO WO2016097219A1 · 2016 [cited by applicant]

WO WO2016100575A1 · 2016 [cited by applicant]

WO WO2016146757A1 · 2016 [cited by applicant]

WO WO2017015154A1 · 2017 [cited by applicant]

WO WO2017100551A1 · 2017 [cited by applicant]

WO WO2017106345A1 · 2017 [cited by applicant]

WO WO2017136202A1 · 2017 [cited by applicant]

WO WO2017149292A1 · 2017 [cited by applicant]

WO WO2018046737A1 · 2018 [cited by applicant]

WO WO2018126112A1 · 2018 [cited by applicant]

WO WO2018126116A1 · 2018 [cited by applicant]

WO WO2018129586A1 · 2018 [cited by applicant]

WO WO2018167621A1 · 2018 [cited by applicant]

WO WO2018187231A2 · 2018 [cited by applicant]

WO WO2018206168A1 · 2018 [cited by applicant]

WO WO2018222925A1 · 2018 [cited by applicant]

Chen H. Exploiting the Intron-splicing Mechanism of Insect Cells to Produce Viral Vectors Harboring Toxic Genes for Suicide Gene Therapy. Mol Ther Nucleic Acids. Nov. 27, 2012;1(11): e57. doi: 10.1038/mtna.2012.48. PMID… [cited by examiner]

Hacein-Bey-Abina et al., “Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1,” J Clin Invest. 2008; 118(9):3132-42. [cited by applicant]

Kramer et al., “In vitro and in vivo comparative study of chimeric liver-specific promoters,” Mol Therapy. 2003; 7(3):375-85. [cited by applicant]

Lu et al., “A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro,” Mol Ther. 2013;21(5):954-63. [cited by applicant]

Lu et al., “A 5′ Noncoding Exon Containing Engineered Intron Enhances Transgene Expression from Recombinant AAV Vectors in vivo,” Hum Gene Ther. 2017;28(1):125-34. [cited by applicant]

PCT International Search Report from PCT/US2019/016354 dated Apr. 30, 2019. [cited by applicant]

Regier et al., “Phenylalanine Hydroxylase Deficiency,” GeneReviews. Jan. 10, 2000; Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: <URL:https://www.ncbi.nlm.nih.gov/books/NBK1504>; Genbank su… [cited by applicant]

Savy et al., “Impact of Inverted Terminal Repeat Integrity on rAAV8 Production Using the Baculovirus/Sf9 Cells System,” Human Gene Therapy Methods. 2017;28(5):277-89. [cited by applicant]

Sibley et al., “Lessons from non-canonical splicing,” Nat Rev Gen. 2016;17(7):407-21. [cited by applicant]

Thöny, “Long-term correction of murine phenylketonuria by viral gene transfer: liver versus muscle,” J Inherit Metab Dis. 2010;33(6):677-80. [cited by applicant]